Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Holding HAE?
Track your performance easily
HAE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.25 - $97.97
Previous Close$75.44
Volume1.50M
Average Volume (3M)599.99K
Market Cap
$3.86B
Enterprise Value$4.79B
Total Cash (Recent Filing)$299.28M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)31.3
Beta1.13
Next Earnings
Feb 11, 2025EPS Estimate
$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding50,223,887
10 Day Avg. Volume5,340,131
30 Day Avg. Volume599,987
Standard Deviation0.12
R-Squared0.03
Alpha-0.00265
Financial Highlights & Ratios
Price to Book (P/B)4.31
Price to Sales (P/S)2.84
Price to Cash Flow (P/CF)19.80
P/FCF Ratio24.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.52
Enterprise Value/Gross Profit6.92
Enterprise Value/Ebitda16.91
Forecast
1Y Price Target
$112.88Price Target Upside49.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Haemonetics News
PremiumCompany Announcements
Haemonetics’ Q2 2025 Earnings Show Strong Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceShares are trading at a discount to peers, providing a compelling entry point with visibility into long-term growth driven by top-line growth, potential multiple expansion, and share buy-backs.
Product InnovationThe redesign and expansion of medical devices like VASCADE XL are seen as key growth drivers for Haemonetics.
Strategic DivestitureThe divestment of the Whole Blood business aligns with management's strategy to focus on higher-growth, higher-margin hospital product portfolios.
Bears Say
Earnings ImpactThe whole blood business divestiture is expected to be modestly EPS dilutive on a net basis, indicating a potential short-term financial impact.
Financial PerformanceThe recent sale of Whole Blood Assets could be a near-term headwind to reported growth, though it may better position the remaining business for future re-acceleration.
Sales DeclinePlasma sales declined 3% organic in F2Q25 similar to the 3% organic decline in F1Q25 given the CSL transition.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $70.25 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Currently, no data Available
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Feb 11, 2025 which is in 51 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Nov 07, 2024. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.073 by $0.047.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is $1.17.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,223,890 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.12 in its last earnings report, beating expectations of $1.073. Following the earnings report the stock price went up 10.709%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Among the largest hedge funds holding Haemonetics Corp.’s share is Royce & Associates LLC. It holds Haemonetics Corp.’s shares valued at 97M.
---
Haemonetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.88 (49.63% Upside)
$112.88 (49.63% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 7.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.47%
12-Months-Change
Fundamentals
Return on Equity
13.97%
Trailing 12-Months
Asset Growth
25.55%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAE Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented strong performance in the Hospital segment and significant growth in the Vascular Closure business, which were offset by declines in Plasma and Blood Center revenues, and challenges in China. The company maintains a positive outlook with increased guidance for organic revenue growth, reflecting confidence in overcoming current challenges.Read More>---
HAE Stock 12 Month Forecast
Average Price Target
$112.88
▲(49.63% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
27/48 ratings generated profit
1 Year Average Return
+7.56%
reiterated a buy rating 4 days ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +7.56% per trade.
---